Krystal Biotech Stock Plummets 16.06% in Two Days, Trading Volume Surges to 1.85 Billion, Ranking 479th in Daily Market
1min read On May 6, 2025, Krystal Biotech (KRYS) experienced a significant drop in its stock price, falling by 14.06% over two consecutive days, resulting in a total decline of 16.06%. The company's trading volume surged to 1.85 billion, marking a 229.36% increase from the previous day, placing it at the 479th position in the daily stock market rankings.
Krystal Biotech reported a net product revenue of $88.2 million for the first quarter of 2025, with a gross margin of 94%. The company's financial performance was bolstered by the approval of VYJUVEK in Europe for the treatment of DEB patients from birth, marking a significant milestone in its global expansion strategy. VYJUVEK, the company's flagship gene therapy, has shown promising results in promoting durable wound healing and has secured over 540 reimbursement approvals in the U.S.
Krystal Biotech is also making strides in its respiratory and ophthalmology programs. The company is enrolling patients in clinical trials for KB407, a treatment for cystic fibrosis, and KB408, a therapy for alpha-1 antitrypsin deficiency lung disease. Additionally, the company has received FDA clearance for KB801, an investigational new drug for the treatment of neurotrophic keratitis, and is preparing to dose the first patient in its Phase 1/2 study for KB801 later this month.
In the oncology sector, Krystal Biotech is conducting clinical trials for inhaled KB707, a treatment for solid tumors of the lung, and intratumoral KB707, a therapy for injectable solid tumors. The company is also advancing its aesthetics portfolio with KB301 and KB304, treatments for dynamic wrinkles of the décolleté and wrinkles, respectively. The company's strong financial position, with $765.3 million in cash and investments, supports its continued investment in research and development across multiple therapeutic areas.
